X Biotech Inc - Understand $xbit stock

$XBIT Market Cap: $212.5 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$32.66M

TTM

Current Assets

$185.0M

Q3 2024

Current Liabilities

$15.99M

Q3 2024

Current Ratio

1157.04%

Q3 2024

Total Assets

$209.9M

Q3 2024

Total Liabilities

$17.74M

Q3 2024

Book Value

$192.1M

Q3 2024

Cash

$183.1M

Q3 2024

P/E

-6.506

Nov 14, 2024 EST

Free Cash Flow

-$23.01M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$0.00	$4.000M	$18.39M	$44.00M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-100.0%	-78.25%	-58.19%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$0.00	$4.000M	$18.39M	$44.00M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$0.00	$651.0K	$5.820M	$34.55M	$0.00	$0.00
Gross Profit	$0.00	$3.359M	$12.57M	$9.449M	$0.00	$0.00
Gross Profit Margin		83.98%	68.36%	21.48%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$4.662M	$6.305M	$9.388M	$18.20M	$7.140M	$5.270M	$7.640M	$10.28M	$6.200M	$7.450M	$1.990M	$1.830M
YoY Change	-26.06%	-32.84%	-48.42%	154.9%	35.48%	-31.02%	-25.68%	65.81%	-16.78%	274.37%	8.74%
% of Gross Profit		187.7%	74.66%	192.61%
Research & Development	$32.85M	$31.54M	$28.27M	$9.527M	$24.09M	$15.73M	$26.42M	$42.49M	$31.31M	$14.33M	$7.935M	$13.33M
YoY Change	4.13%	11.59%	196.71%	-60.45%	53.2%	-40.49%	-37.81%	35.69%	118.51%	80.58%	-40.47%
% of Gross Profit		939.09%	224.81%	100.83%
Depreciation & Amortization	$1.744M	$2.600M	$2.600M	$2.200M	$2.400M	$2.400M	$1.484M	$698.0K	$699.0K	$664.0K	$784.0K	$950.0K
YoY Change	-32.92%	0.0%	18.18%	-8.33%	0.0%	61.73%	112.61%	-0.14%	5.27%	-15.31%	-17.47%
% of Gross Profit		77.4%	20.68%	23.28%
Operating Expenses	$37.51M	$37.85M	$37.66M	$27.73M	$31.23M	$20.99M	$34.06M	$52.76M	$37.51M	$21.78M	$9.925M	$15.16M
YoY Change	-0.9%	0.51%	35.82%	-11.23%	48.77%	-38.36%	-35.45%	40.66%	72.24%	119.43%	-34.53%
Operating Profit	-$37.51M	-$34.49M	-$25.08M	-$18.28M	-$31.23M	-$20.99M	-$34.06M	-$52.76M	-$37.51M	-$21.78M	-$9.925M
YoY Change	8.76%	37.51%	37.24%	-41.48%	48.77%	-38.36%	-35.45%	40.66%	72.24%	119.43%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	$12.31M	$1.023M	-$244.0K	$5.950M	-$320.0K	-$150.0K	$910.0K	$0.00	$10.00K	$50.00K	$0.00	$0.00
YoY Change	1103.71%	-519.26%	-104.1%	-1959.38%	113.33%	-116.48%		-100.0%	-80.0%
% of Operating Profit
Other Income/Expense, Net	$883.0K	$902.0K	-$376.0K	$5.449M	$749.7M	-$144.0K	$909.0K	$2.000K	$27.00K	$54.00K	-$2.000K
YoY Change	-2.11%	-339.89%	-106.9%	-99.27%	-520715.28%	-115.84%	45350.0%	-92.59%	-50.0%	-2800.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$24.31M	-$33.59M	-$25.46M	-$12.83M	$718.5M	-$21.14M	-$33.15M	-$8.749M	-$6.544M	-$3.494M	-$9.930M	-$15.16M
YoY Change	-27.61%	31.93%	98.47%	-101.79%	-3498.87%	-36.24%	278.9%	33.69%	87.29%	-64.81%	-34.5%
Income Tax	$244.0K	-$688.0K	-$8.044M	-$1.606M	$49.82M	$0.00		$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income					6.93%
Net Earnings	-$24.56M	-$32.90M	-$17.41M	-$11.22M	$668.6M	-$21.14M	-$33.15M	-$52.76M	-$37.48M	-$21.72M	-$9.927M	-$15.16M
YoY Change	-25.36%	88.93%	55.19%	-101.68%	-3263.16%	-36.24%	-37.17%	40.76%	72.54%	118.84%	-34.52%
Net Earnings / Revenue		-822.5%	-94.67%	-25.5%
Basic Earnings Per Share	-$0.81	-$1.08	-$0.58	-$0.36	$17.17	-$0.59	-$0.95
Diluted Earnings Per Share	-$0.81	-$1.08	-$0.58	-$0.36	$14.44	-$0.59	-$0.95	-$1.628M	-$1.217M	-$684.7K	-$313.1K	-$477.9K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$200.0M	$217.5M	$237.0M	$237.4M	$714.6M	$15.80M	$31.80M	$34.30M	$91.10M	$57.30M	$7.200M	$4.200M
YoY Change	-8.03%	-8.23%	-0.18%	-66.78%	4422.78%	-50.31%	-7.29%	-62.35%	58.99%	695.83%	71.43%
Cash & Equivalents	$200.0M	$157.3M	$237.0M	$237.4M	$714.6M	$15.80M	$31.80M	$34.30M	$91.10M	$57.30M	$7.200M	$4.200M
Short-Term Investments	$0.00	$60.17M
Other Short-Term Assets	$760.0K	$601.0K	$934.0K	$2.800M	$1.700M	$1.200M	$1.600M	$2.600M	$2.000M	$700.0K	$400.0K	$200.0K
YoY Change	26.46%	-35.65%	-66.64%	64.71%	41.67%	-25.0%	-38.46%	30.0%	185.71%	75.0%	100.0%
Inventory
Prepaid Expenses
Receivables	$860.0K	$1.216M	$0.00	$4.100M
Other Receivables	$75.00K	$548.0K	$8.953M	$81.70M
Total Short-Term Assets	$201.7M	$219.8M	$246.9M	$325.9M	$716.3M	$17.00M	$33.30M	$36.90M	$93.00M	$58.10M	$7.700M	$4.400M
YoY Change	-8.24%	-10.95%	-24.25%	-54.5%	4113.53%	-48.95%	-9.76%	-60.32%	60.07%	654.55%	75.0%
Property, Plant & Equipment	$24.90M	$26.26M	$28.31M	$27.30M	$25.20M	$27.30M	$29.60M	$30.10M	$16.30M	$4.100M	$3.400M	$4.100M
YoY Change	-5.19%	-7.23%	3.69%	8.33%	-7.69%	-7.77%	-1.66%	84.66%	297.56%	20.59%	-17.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00	$500.0K	$400.0K
YoY Change			-100.0%	25.0%
Total Long-Term Assets	$24.90M	$26.26M	$28.31M	$27.80M	$100.6M	$27.30M	$29.70M	$30.20M	$16.40M	$4.100M	$3.400M	$4.100M
YoY Change	-5.19%	-7.23%	1.82%	-72.37%	268.5%	-8.08%	-1.66%	84.15%	300.0%	20.59%	-17.07%
Total Assets	$226.6M	$246.1M	$275.2M	$353.7M	$816.9M	$44.30M	$63.00M	$67.10M	$109.4M	$62.20M	$11.10M	$8.500M
YoY Change
Accounts Payable	$2.516M	$2.408M	$2.069M	$2.500M	$2.100M	$1.700M	$1.700M	$4.400M	$4.800M	$1.600M	$600.0K	$500.0K
YoY Change	4.49%	16.38%	-17.24%	19.05%	23.53%	0.0%	-61.36%	-8.33%	200.0%	166.67%	20.0%
Accrued Expenses	$3.501M	$1.603M	$1.374M	$1.400M	$4.200M	$1.300M	$1.100M	$3.500M	$1.500M	$1.500M	$300.0K	$600.0K
YoY Change	118.4%	16.67%	-1.86%	-66.67%	223.08%	18.18%	-68.57%	133.33%	0.0%	400.0%	-50.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.100M	$4.066M	$3.453M	$4.000M	$60.20M	$2.900M	$2.800M	$8.000M	$6.300M	$3.100M	$800.0K	$1.100M
YoY Change	50.02%	17.75%	-13.68%	-93.36%	1975.86%	3.57%	-65.0%	26.98%	103.23%	287.5%	-27.27%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.669M	$1.576M	$1.466M	$1.100M	$1.100M	$0.00	$0.00	$0.00	$0.00		$0.00	$0.00
YoY Change	5.9%	7.5%	33.27%	0.0%
Total Long-Term Liabilities	$1.669M	$1.576M	$1.466M	$1.100M	$1.100M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	5.9%	7.5%	33.27%	0.0%
Total Liabilities	$7.769M	$5.701M	$5.792M	$5.100M	$61.20M	$2.900M	$2.800M	$8.000M	$6.300M	$3.100M	$800.0K	$1.100M
YoY Change	36.27%	-1.57%	13.57%	-91.67%	2010.34%	3.57%	-65.0%	26.98%	103.23%	287.5%	-27.27%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017
Basic Shares Outstanding	30.44M	30.44M	30.04M	30.82M	38.95M	35.80M	34.88M
Diluted Shares Outstanding	30.44M	30.44M	30.04M	30.82M	46.32M	35.80M	34.88M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $212.47 Million

About XBiotech Inc

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 92 full-time employees. The company went IPO on 2015-04-15. The firm's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The firm is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. The company has various candidate products including Natrunix. The company has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Industry: Pharmaceutical Preparations Peers: Candel Therapeutics Inc Greenwich Lifesciences Inc Biostax Corp INmune Bio Inc Syros Pharmaceuticals Inc Nuvectis Pharma Inc Olema Pharmaceuticals Inc Praxis Precision Medicines Inc Shattuck Labs Inc